ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0031

A Systematic Approach for Identifying Causal Variants and Their Target Genes on JIA Risk Haplotypes

Kaiyu Jiang1, tao liu2, Ryan Tewhey3, Susan Kales3, Yungki Park4 and James N Jarvis5, 1University at Buffalo, Buffalo, NY, 2Roswell Park Cancer Institute, Buffalo, NY, 3Jackson Laboratories, Bar Harbor, ME, 4University at Buffalo Jacobs School of Medicine & Biomedical Sciences, Buffalo, NY, 5University at Buffalo Jacobs School of Medicine, Buffalo, NY

Meeting: ACR Convergence 2023

Keywords: Epigenetics, genetics, genomics, Juvenile idiopathic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 12, 2023

Title: (0013–0039.5) Genetics, Genomics & Proteomics Poster

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: GWAS have identified multiple genetic regions that confer risk for juvenile idiopathic arthritis (JIA).However, identifying the single nucleotide polymorphisms (SNPs) that drive disease risk has been impeded by the fact that the SNPs used to identify risk loci are in linkage disequilibrium (LD) with hundreds of other SNPs. Since the causal SNPs remain unknown, it is difficult to identify target genes, and thus use genetic information to elucidate disease biology and inform patient care. We have therefore developed a functional genomics pipeline to identify causal variants and their target genes on JIA risk haplotypes.

Methods: We designed 180 bp oligonucleotides (“oligos”) representing 7,312 SNPs in LD with the tag SNPs on JIA risk loci (r2 = 0.80).Oligos were bar coded and cloned into a green fluorescence protein (GFP)-carrying plasmid vector behind a minimal promoter. We transfected our oligo libraries into myeloid K562 cells to conduct a massively parallel reporter assay (MPRA) in which GFP expression for each of the 7,312 SNPs was compared to the common allele. We then used 3D chromatin data to identify the chromatin loops harboring the enhancers carrying SNPs that screen positive on MPRA. We used K562 cells stably transfected with the epigenome editing enzyme dCas-KRAB and gRNAs across the enhancer regions in the TRAF1 and LNPEP/ERAP2 loci, inducing dCas-KRAB with doxycycline and using qrtPCR to query expression levels of genes within the same chromatin loops.

Results: We identified n=44 SNPs that showed a significant difference in gene expression (FC > 2.0, FDR = 0.05) when compared to the common allele. After stimulating K562 cells with IFNγ (250 ng/ml), we identified an additional 42 SNPs that showed significant effects on gene expression that were not identified in unstimulated cells. In many cases, we identified multiple alleles on the same haplotype, although these alleles were not necessarily within the same functional element (e.g., intergenic vs intronic enhancers). Ablating the intergenic enhancer harboring rs10985080 on the TRAF1 haplotype using CRISPRi significantly reduced the expression of PHF1, but not C5, which is in the same chromatin loop. Using a similar approach for an intergenic enhancer in the LNPEP/ERAP2 locus, we found reduced expression of both LNPEP and ERAP2 but not CAST.

Conclusion: We demonstrate proof-of concept for identifying causal variants on JIA risk haplotypes based on observed functional properties that distinguish them from the SNPs in which they are in LD. We also demonstrate that, once these variants are identified, target genes can be quickly identified using publicly available 3D chromatin data and additional functional assays such as CRISPRi.

Supporting image 1

CRISPi identifies target genes of enhancers harboring JIA-associated variants detected on MPRA. (A). gRNAs used for epigenome editing experiments. The scrambled gRNA is a non-targeting negative control gRNA. For each experiment, 4 gRNAs were targeted to the functional regions of intergenic enhancers in the TRAF1 locus and the ERAP2/LNPEP locus. (B) Attenuation of the intergenic enhancer at the TRAF1 locus significantly reduced expression of PHF19, but not C5 (not shown). Off-target effects are monitored by showing that these gRNAs have no effect on HBE1 expression, but that gRNAs directed to an enhancer known to regulated HBE1 attenuates expression. Bar graphs summarize the results of 4 independent experiments. (C) Attenuating the intergenic enhancer in the LNPEP/ERAP2 locus reduces expression of both LNPEP and ERAP2, but not the adjacent gene, CAST, nor the HBE1 gene (not shown). In each experiment, scrambled versions of the gRNAs had no effect on expression of the putative targets. **p<0.01; ***p<0.001.


Disclosures: K. Jiang: None; t. liu: None; R. Tewhey: None; S. Kales: None; Y. Park: None; J. Jarvis: None.

To cite this abstract in AMA style:

Jiang K, liu t, Tewhey R, Kales S, Park Y, Jarvis J. A Systematic Approach for Identifying Causal Variants and Their Target Genes on JIA Risk Haplotypes [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/a-systematic-approach-for-identifying-causal-variants-and-their-target-genes-on-jia-risk-haplotypes/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-systematic-approach-for-identifying-causal-variants-and-their-target-genes-on-jia-risk-haplotypes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology